Literature DB >> 11576287

Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis.

R. A. K. Samlal1, J. Van Der Velden, T. Van Eerden, M. S. Schilthuis, D. Gonzalez Gonzalez, F. B. Lammes.   

Abstract

Samlal RAK, van der Velden J, van Eerden T, Schilthuis MS, Gonzalez Gonzalez D, Lammes FB. Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer 1998; 8: 78-84. The purpose of the present study was to evaluate the clinical aspects and prognosis of patients with tumor recurrence in surgically treated stage IB and IIA cervical carcinoma patients. Two hundred and seventy-one stage IB and IIA cervical carcinoma patients underwent a Wertheim Okabayashi radical hysterectomy with pelvic lymphadenectomy. The median follow-up time was 60 months. Recurrence occurred in 27 patients (10%): 14 had a pelvic recurrence and 13, and extrapelvic recurrence. The site of recurrence was influenced by various pathological factors as well as by the primary treatment mode. 77% of recurrences were detected within three years after primary treatment. The median recurrence-free interval in patients with a pelvic recurrence was significantly shorter than in patients with an extrapelvic recurrence (14 months vs. 17 months, P = 0.03). The mortality rate of the group of patients with recurrent disease was 85% (23/27). Patients with a pelvic central recurrence had a significantly better outcome than did patients whose recurrences were located at the pelvic sidewall. Two patients with a pulmonary recurrence were treated with surgery and show no evidence of disease after 4 and 8 years respectively, of follow-up. The overall detection rate of recurrent disease by routine follow-up was only 36%. However, asymptomatic patients had a significantly better prognosis when compared with symptomatic patients. Therefore, we recommend frequent follow-up visits during the first 3 years after primary treatment to detect recurrence in an early stage.

Entities:  

Year:  1998        PMID: 11576287     DOI: 10.1046/j.1525-1438.1998.09759.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Follow-up for women after treatment for cervical cancer.

Authors:  L Elit; A W Fyles; T K Oliver; M C Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

2.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

3.  Cervical cancer recurrence presenting as abdominal wall mass and accompanying cellulitis.

Authors:  Jesse Chou; Lauren Strzyzewski; Caitlin Timmers; Anna Hoekstra
Journal:  Gynecol Oncol Rep       Date:  2020-08-03

4.  The Clinical Aspects and Prognostic Factors Concerning Survival in Patients With Recurrent Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiotherapy.

Authors:  Hui-Ting Zhu; Wen-Juan Yan; Yu-Hua Gao
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 5.  Follow-up protocols for women with cervical cancer after primary treatment.

Authors:  Anne Lanceley; Alison Fiander; Mary McCormack; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2013-11-25

6.  Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.

Authors:  Yuji Ikeda; Akiko Furusawa; Ryo Kitagawa; Aya Tokinaga; Fuminori Ito; Masayo Ukita; Hidetaka Nomura; Wataru Yamagami; Hiroshi Tanabe; Mikio Mikami; Nobuhiro Takeshima; Nobuo Yaegashi
Journal:  J Gynecol Oncol       Date:  2016-05       Impact factor: 4.401

7.  Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer.

Authors:  Tae Wook Kong; Joo Hyuk Son; Jiheum Paek; Suk Joon Chang; Hee Sug Ryu
Journal:  J Gynecol Oncol       Date:  2019-07-22       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.